AACCE Investments
ScreenerStocksIndicesPicksETFsBlogPricing

© 2026 ACCE Investments. All rights reserved.

ACCE Investments - Institutional-grade stock research for retail investors | BetaList
IndicesStocksETFsScreenerBlogGlossaryCompareMarket dataAdvisors
TermsPrivacyCookiesDisclaimerLegal noticeProfessional termsAboutContact
SPOK

Spok Holdings Inc. Common Stock (SPOK) fair value

Healthcare · Health Information Services · NASDAQ · United States
$10.30-3.83%
Market cap $224MNext earnings 2026-10-28Updated Oct 18, 2026
Add earnings to calendarGoogle
Our verdict
Trades 17% below our fair value
Price
$10.30
Model fair valueConfidence: good
$12.34
Model range
$8.36 to $16.02
Fair value $12.34
Price $10.30
4 models fit Spok Holdings Inc. Common Stock and they partly agree: 2 of 4 land within 15% of the average.
Two or more of our models back this value.
Discount(i)Bronze59
Valued as a mature, profitable company: Discounted cash flow, P/E comparison, EV/EBITDA comparison, and Graham number.
ACCE opinionSpok Holdings Inc. Common Stock (SPOK)
Fair value (4 models)
$12.34
ACCE price target
$10.80
Rating
Undervalued
Horizon
12 months
Fair value published on 14 Oct 2026, 00:00 CEST; previously $10.98 since 29 Sept 2026, 00:00 CEST.
ACCE price target published on 15 Oct 2026, 00:00 CEST.
Rating published on 18 Oct 2026, 15:06 CEST.
Price used: $10.30 at the close on 23 Oct 2026, 22:00 CEST.
Models: Discounted cash flow, EV/EBITDA comparison, Graham number, and P/E comparison.
Fair value: the average of the applicable valuation models (discounted cash flow, multiples, residual income, dividend discount, shareholder yield), each run on the latest financial statements and the market price shown. Opinion columns (fair value, target, rating) are shown apart from the data. Full methodology: acceinvestments.com/data/how-we-value-stocks
Full methodology
Conflicts of interest: The author holds no personal position in this security. General statement
Produced by ACCE Investments (acceinvestments.com)
Data
Price vs fair value
16.5% below
+19.8% to fair value
ACCE score
48
out of 100
Analysts
100% buy
1 covering
P/E
18.8x
forward 10.2x
1-year return
-36.3%
Dividend yield
12.07%

Spok Holdings Inc. Common Stock in four questions

Plain answers, details below
Free accounts get 5 full stock pages a month, including the four answers.
OverviewAsk ACCEValuationQualityAnalystsSmart MoneyCompareNews and Record

Overview

ACCE thesis

Spok Holdings sells the paging and communications software that hospitals use to route clinical alerts, staff pages and secure messages between devices, with its Spok Care Connect platform the main product for hospital customers. The core advantage is installed base: hospitals that have built alerting workflows around Spok tend to stay, and the business still earns a 60.4% gross margin and 19.9% operating margin. Revenue is shrinking, though, down 1.9%, so the thesis rests on whether the margin structure can hold while the top line stabilizes. The stock trades at 18.8 times trailing earnings but 10.2 times forward earnings, a gap that implies analysts expect earnings to rise even as sales fall. Return on equity of 8.4% is modest, and the score of 48 out of 100 along with no index membership suggests this is a small, under-followed name that needs a closer look at cash flow and customer retention before it earns a place in the book.

AI-assisted·How I use AIWritten Oct 18, 2026
⚠ Investor warnings · 2 flagsAI-assisted·How I use AI
  • moderate
    Revenue and earnings shrinking
    Revenue is down 1.9% year on year, earnings are down 10.4%, and the 5-year revenue CAGR is -1.2%. The top line has been contracting for some time, not just one quarter.
  • moderate
    Quality metrics mixed with weak momentum
    A 60.4% gross margin and 19.9% operating margin look healthy, but the ACCE score of 48 with momentum at 31 suggests the market is not rewarding the business. Debt/equity of 0.05 leaves little balance sheet risk.

AI research notes

AI-assisted·How I use AIWritten Oct 18, 2026 · figures from 2026-06-30 · prices to Oct 23, 2026
Why it could do well
  • Free cash flow over the last 12 months reached $25M, and the stock's free cash flow yield stands at 11.4%.
  • The stock trades at a forward P/E of 10.2x, well below the sector median forward P/E of 24.3x.
Why it could disappoint
  • Revenue fell 1.9% year over year, and the five-year average annual revenue growth is negative at -1.2%.
  • Diluted share count rose 2.5% last fiscal year, diluting existing shareholders' stake in the company.
  • Return on equity of 8.4% and return on invested capital of 8.5% are modest returns on the capital the business uses.
Each chip shows the exact figure and where it comes from. A claim without a source is not published.

Next results

Oct 28, 2026
We update the fair value about 2 days after the results, once the new figures are filed.Add to calendarGoogle

Walk me through this stock

Plain-English pros, cons, and what to watch. Pro feature.

PRO

Ask ACCE

Valuation

INVESTOR
Where SPOK's valuation models land
Price
$10.30
Model fair value
$12.34
Model range
$8.36 to $16.02
Fair value $12.34
Price $10.30
The price sits inside the model range.
Model
Fair value
Upside
Discounted cash flow
EV/EBITDA comparison
Graham number
P/E comparison
Create a free account: 5 full stock pages a month, no card.

See what each model says, the assumptions behind it, the bad, normal and good cases, and why the fair value changed.

Quality

INVESTOR
Quality and conviction INVESTOR FEATURE

The full quality picture: a reason under every score, how the scores moved, and the conviction breakdown.

  • +A plain reason under every score
  • +Conviction breakdown and growth / value / quality / momentum scores
  • +Score history: how each score moved over time

Analysts

Wall Street consensus

Bullish100% buy · 1 covering analyst
● Strong buy 1● Buy 0● Hold 0● Sell 0● Strong sell 0
Analyst intelligence INVESTOR FEATURE

The full analyst picture: the price-target distribution against the current price, forward consensus estimates, and how ACCE's own models compare.

  • +Price-target low / average / high vs the current price, with implied upside
  • +Forward revenue and EPS consensus by fiscal year
  • +ACCE fair-value models lined up against the Street

Smart Money

PRO

In one line

Trades are only made public after a delay. We show the delay so you know how old the news is.

Company insiders
No trades filed
Last 90 days
Congress
No trades filed
Last 180 days
Average delay
No trades filed
From trade to public filing
Do politicians beat the market? Our backtest →
Smart money tracking PRO FEATURE

Follow the informed money: 13F position changes, insider and Congress trades, and 13D activist filings.

  • +Quarter-over-quarter institutional position changes
  • +Every insider and Congress trade, with how late it was disclosed
  • +Active 13D activist filings and top holders

Compare

Where it sits vs peers

News and Record

Press releases mentioning this company

Recent performance

1 week
-2.9%
1 month
-1.0%
3 months
-2.7%
6 months
-9.4%
YTD
-21.9%
1 year
-36.3%

SEC filings

Recommendation history, last 12 months

DateTypeNewPreviousPrice
18 Oct 2026, 15:06 CESTRatingUndervaluedfirst publication$10.61
15 Oct 2026, 00:00 CESTACCE price target$10.80first publication$10.83
14 Oct 2026, 00:00 CESTFair value$12.33$10.98$10.74
29 Sept 2026, 00:00 CESTFair value$10.98$11.10$10.46
15 Sept 2026, 00:00 CESTFair value$11.10$11.26$10.65
10 Sept 2026, 00:00 CESTFair value$11.26$11.40$10.64
30 Aug 2026, 00:00 CESTFair value$11.40$11.87$10.65
27 Aug 2026, 00:00 CESTFair value$11.87$11.43$10.45
25 Aug 2026, 00:00 CESTFair value$11.43$11.87$10.43
22 Aug 2026, 00:00 CESTFair value$11.87$11.74$10.48

This analysis is not personalised investment advice and does not take your situation, objectives or risk tolerance into account. ACCE Investments is not an authorised investment firm.

Investing in shares carries a risk of losing capital. The value of an investment can go down as well as up.

Valuation horizon: 12 months from the publication date.

Conflicts of interest. ACCE Investments is operated by Adrien Chantreuil, who may hold personal positions in the securities analysed. Positions are declared on each security. ACCE receives no payment from the companies analysed or from any intermediary for this analysis.

Get the full SPOK page, free

Every model, the scenarios, fair value history, AI notes and the four questions. 5 full stock pages every month on the free plan, no card.

Free accounts get 5 full stock pages a month, including the full page.

Snapshot

Growth7Value80Quality75Momentum31Total48
Valuation
Trailing P/E
18.8x
Forward P/E
10.2x
PEG
no data
P/B
1.57x
EV / Revenue
1.5x
Book value/sh
$6.69
Enterprise value
$209M
Profitability
ROE
8.4%
FCF yield
11.25%
ROIC
8.5%
Health and risk
Debt / equity
0.05
Dividend yield
12.07%
Beta
0.45

Price

-36.3% · 1Y

Ask anything about SPOK

Answered from Spok Holdings Inc. Common Stock fundamentals + recent valuations. Every number shows its source and date.

This stock Peer Peer median weaker → stronger
P/Ebetter than 50% of peers
low 0.0x18.8xhigh 45.8x
ROEbetter than 83% of peers
low -29%8%high 26%
Div yieldbetter than 100% of peers
low 0.0%12.1%high 12.1%

Peers

Prices Oct 23, 2026
CompanyPriceFair valuevs fair valueP/EROEQualityScore
SPOK Spok Holdings Inc. Common Stock$10.30$1217% below18.8x8.4%7548
ASCN.SW Ascom Holding AGCHF 5.72CHF 720% below11.0x25.7%7873
SY So-Young International Inc. American Depository Shares$2.11----15.0%4348
AMWL American Well Corporation Class A Common Stock$13.57----29.1%4342
CARA.ST Carasent AB (publ)kr 27.00kr 1584% above45.8x4.8%6658
OPRX OptimizeRx Corporation Common Stock$9.15$93% below38.1x3.7%5451
SUS.ST Surgical Science Sweden AB (publ)kr 57.20kr 562% above31.4x2.1%7063

Sector report card

Where SPOK ranks against its sector peers on each metric.

Computing percentiles…
  • Business Wire•Oct 19, 2026
    Spok appoints Shiv Gopalkrishnan as EVP & General Manager
  • Business Wire•Sep 22, 2026
    Spok Supports All Leading Hospitals Named to U.S. News & World Report’s 2026-2027 Best Children’s Hospitals Honor Roll
  • Business Wire•Aug 6, 2026
    Spok-Powered Hospitals Recognized on 2026-2027 U.S. News & World Report's Best Hospitals Honor Roll
5 more press releases · full archive on Investor+.INVESTOR
40 filings
October 2026
Oct 2
Form 4Insider transactionPeriod 2026-10-01
View on SEC →
Oct 2
Form 4Insider transactionPeriod 2026-10-01
View on SEC →
Oct 2
Form 4Insider transactionPeriod 2026-10-01
View on SEC →
37 more filings + AI summaries on Investor+.INVESTOR